Nebulized albuterol versus levalbuterol in pediatric and adult patients: A review

Formulary

Volumn 44, Issue 4, 2009, Pages 108-118

  Crader, Marsha ^a   Borkowski, Jaime ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b OSF Saint Anthony Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LEVALBUTEROL; PLACEBO; PREDNISONE; SALBUTAMOL;

ADULT; AGE DISTRIBUTION; AIRWAY OBSTRUCTION; ANXIETY; ASTHMA; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART RATE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LUNG FUNCTION TEST; MIGRAINE; NEBULIZATION; NERVOUSNESS; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; REIMBURSEMENT; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; TREATMENT INDICATION; TREMOR;

EID: 77951779773     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Kruzikas DT, Jiang HJ, Remus D, Barrett ML, Coffey RM, Andrews R. Respiratory diseases: Adult asthma, pediatric asthma, and chronic obstructive pulmonary disease. In: Preventable hospitalizations: Window into preventative and primary care, 2000. US Department of Health and Human Services. AHRQHCUP Fact Book No. 5: 30-33.
2. Moorman JE, Rudd RA, Johnson CA, et al. National surveillance tor asthma-United States, 1980-2004. MMWR Surveill Summ. 2007; 56: 1-54.
3. Mitra S, Ugur M, Ugur O, Goodman HM, Mc-Cullough JR, Yamaguchi H. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998; 53: 347-354.
4. Penn RB, Frielle T, McCullough JR, Aberg C, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human beta 1-and beta 2-adrenergic receptors. Clin Rev Allergy Immunol. 1996; 1 4: 37-45.
5. Lötvall J, Palrnqvist M, Arvidsson P, Maloney A, Ventresea GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol. 2001; 108: 726-731.
6. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. J Allergy Clin Immunol. 2005; 116: 65-72.
7. Agrawal DK, Ariyarathna K, Kelbe PW. (S)-albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol. 2004; 113: 503-510.
8. Volcheck GW, Kelkar P, Bartemes KR, Gleich GJ, Kita H. Effects of (R) - and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy. 2005; 35: 1341-1346.
9. Yamaguchi H, McCullough JR. S-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol. 1996; 14: 47-55.
10. l0. Johansson F, Rydberg I, Aberg G, Andersson RG. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol. 1996; 14: 57-64.
11. 2-agonist enantiomers of albuterol [abstract]. J Allergy Clin Immunol. 2000; 105 (suppl) : S292. Abstract 858.
12. Volcheck GW, Gleich GJ, Kita H. Pro-and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunol. 1998; 101: S35.
13. Walle T, Eaton EA, Walle UK, Pesola GR. Stereoselective metabolism of RS-albuterol in humans. Clin Rev Allergy Immunol. 1996; 14: 101-113.
14. Bennett JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax. 1997; 52: 458-464.
15. Thompson Healthcare. Micromedex Healthcare Series (2008). http://www.thomsonhc.com. Accessed March 24, 2009.
16. Scott VL, Frazee LA. Retrospective comparison of nebulized levalbuterol and albuterol for adverse events in patients with acute airflow obstruction. Am J Ther. 2003; 10: 341-347.
17. Lam S, Chen J. Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients. Am J Health Syst Pharm. 2003; 60: 1971-1975.
18. Truitt T, Wifko J, Halpern M. Levalbuterol compared to racemic albuterol: Efficacy and outcomes in patients hospitalized with COPD and asthma. Chest. 2003; 123: 128-135.
19. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: Results of a pilot study. Am J Emerg Med. 2004; 22: 29-36.
20. Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005; 23: 842-847.
21. Nowak R, Emerman C, Hanrahan JP, et al; XO-PENEX Acute Severe Asthma Study Group. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006; 24: 259-267.
22. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 1999; 103: 615-621.
23. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA; Levalbuterol Pediatric Study Group. Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001; 108: 938-945.
24. Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pubnonol. 2005; 40: 477-486.
25. Carl JC, Myers TR, Kirchner HL, Keresmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003; 143: 731-736.
26. Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med. 2005; 46: 29-36.
27. Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care. 2005; 21: 415-419.
28. Ralston ME, Euwema MS, Knecht KR, Ziolkowski TJ, Coakley TA, Cline SM. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: A randomized controlled trial. J Emerg Med. 2005; 29: 29-35.
29. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3) : Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007
30. [erratum in J Allergy Clin Immunol. 2008;121:1330].
31. J Allergy Clin Immunol 2007;120(5 suppl):S94-138.
32. Global Initiative for Chronic Obstructive Pulmonary Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2008). http://www.goldcopd.com. Accessed March 30, 2009.
33. Xopenex [package insert]. Marlborough, MA: Sepracor Inc.; 2005.
34. Red Book. February 2009 update. Montvale, NJ: Thomson PDR; 2009.
35. Bureau of Labor Statistics. Occupational outlook handbook, 2008-09 edition: Respiratory therapists. United States Department of Labor, http://www.bls.gov./oco/ocos084.htm. Accessed March 24, 2009.
36. Asmus MJ, Hendeles, L. Levalbuterol nebulizer solution: Is it worth five times the cost of albuterol? Pharmacotherapy. 2000; 20: 123-129.
37. Department of Health and Human Services Office of Inspector General. Comparison of average sales prices to widely available market prices for inhalation drugs. July 2008. http://www.oig.hhs.gov/oei/reports/oei-03-07-00190. pdf. Accessed March 24, 2009.